Outlook Therapeutics, Inc. (OTLK)
0.4882
-0.01
(-2.36%)
USD |
NASDAQ |
Oct 16, 16:00
0.4918
0.00 (0.00%)
After-Hours: 20:00
Outlook Therapeutics Enterprise Value : 98.53M for Oct. 16, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 16, 2026 | 98.53M |
| October 15, 2026 | 100.74M |
| October 14, 2026 | 95.16M |
| October 13, 2026 | 112.67M |
| October 12, 2026 | 116.66M |
| October 09, 2026 | 119.24M |
| October 08, 2026 | 112.71M |
| October 07, 2026 | 117.58M |
| October 06, 2026 | 114.21M |
| October 05, 2026 | 118.61M |
| October 02, 2026 | 118.14M |
| October 01, 2026 | 114.77M |
| September 30, 2026 | 114.49M |
| September 29, 2026 | 124.26M |
| September 28, 2026 | 123.39M |
| September 25, 2026 | 126.84M |
| September 24, 2026 | 129.89M |
| September 23, 2026 | 130.99M |
| September 22, 2026 | 137.45M |
| September 21, 2026 | 135.59M |
| September 18, 2026 | 129.29M |
| September 17, 2026 | 134.60M |
| September 16, 2026 | 133.84M |
| September 15, 2026 | 133.11M |
| September 14, 2026 | 126.54M |
| Date | Value |
|---|---|
| September 11, 2026 | 130.67M |
| September 10, 2026 | 130.90M |
| September 09, 2026 | 127.66M |
| September 08, 2026 | 127.02M |
| September 04, 2026 | 131.89M |
| September 03, 2026 | 128.62M |
| September 02, 2026 | 124.37M |
| September 01, 2026 | 123.77M |
| August 31, 2026 | 125.70M |
| August 28, 2026 | 127.85M |
| August 27, 2026 | 127.14M |
| August 26, 2026 | 123.81M |
| August 25, 2026 | 126.93M |
| August 24, 2026 | 121.13M |
| August 21, 2026 | 128.28M |
| August 20, 2026 | 133.72M |
| August 19, 2026 | 136.30M |
| August 18, 2026 | 138.16M |
| August 17, 2026 | 132.96M |
| August 14, 2026 | 148.71M |
| August 13, 2026 | 173.48M |
| August 12, 2026 | 213.00M |
| August 11, 2026 | 218.61M |
| August 10, 2026 | 222.35M |
| August 07, 2026 | 198.03M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Valion Bio, Inc. | 23.13M |
| Agenus, Inc. | 522.06M |
| Amgen, Inc. | 277.12B |
| Anika Therapeutics, Inc. | 254.23M |
| BioCryst Pharmaceuticals, Inc. | 2.472B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -20.32M |
| Revenue (Quarterly) | 0.0087M |
| Total Expenses (Quarterly) | 20.33M |
| EPS Diluted (Quarterly) | -0.1486 |
| Gross Profit Margin (Quarterly) | -254.0% |
| Profit Margin (Quarterly) | -233.6K% |
| Earnings Yield | -231.7% |
| Normalized Earnings Yield | -199.18 |